Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01902316|
Recruitment Status : Completed
First Posted : July 18, 2013
Last Update Posted : July 18, 2013
|Condition or disease|
|Diabetes Mellitus, Type 2|
The procedure of clinical study was:
- to get plasma samples from hospital;
- digestion of plasma protein-mixture by trypsin;
- run mass spectrometry and monitor the amount of target HSA-peptides.
|Study Type :||Observational|
|Actual Enrollment :||389 participants|
|Official Title:||Clinical Verification for Early Diagnosis of Type 2 Diabetes Mellitus by Standard-Free, Label-Free LC-MS/MS Quantification of Glycated Peptides|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
- measurement of the amount of plasma peptides [ Time Frame: two years ]The investigators have found 8 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference between normal people and diabetes patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01902316
|Principal Investigator:||Yulin Deng, Ph.D.||School of Life Science, BIT|